GRCE · CIK 0001444192 · operating
Grace Therapeutics, Inc. is a biopharmaceutical company developing pharmaceutical treatments for rare and orphan diseases, with a primary focus on the Canadian market. The company's clinical pipeline includes GTX-104, an intravenous infusion designed to treat subarachnoid hemorrhage, GTX-102, an oral mucosal spray formulation of betamethasone for Ataxia-Telangiectasia neurological symptoms, and GTX-101, a topical bioadhesive film for postherpetic neuralgia pain management. The company is incorporated in Delaware and headquartered in Princeton, New Jersey.
Grace Therapeutics rebranded from its former identity as Acasti Pharma Inc. in October 2024, reflecting a strategic shift in its therapeutic focus. The company operates with a small team of six full-time employees and maintains a lean operational structure typical of early-stage clinical-stage biotechnology firms. As a Nasdaq-listed entity, the company is positioned within the pharmaceutical preparations segment of the healthcare and biotechnology industry.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-0.79 | $-0.79 | +41.5% | |
| 2024 | $-1.35 | $-1.35 | -42.1% | |
| 2023 | $-0.95 | $-0.95 | — | |
| 2022 | — | — | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-03-31 | 2025-06-23 | 0001140361-25-023259 | SEC ↗ |
| 2024-03-31 | 2024-06-21 | 0000950170-24-075875 | SEC ↗ |
| 2023-03-31 | 2023-06-23 | 0000950170-23-029498 | SEC ↗ |
| 2022-03-31 | 2022-06-21 | 0000950170-22-011842 | SEC ↗ |
| 2021-03-31 | 2021-06-22 | 0001171843-21-004462 | SEC ↗ |
| 2020-03-31 | 2020-06-29 | 0001171843-20-004613 | SEC ↗ |